Shan Jiang

1) Analyzed large-scale omics datasets to identify key biological patterns and therapeutic targets in metabolic diseases. 2) Conducted data mining and custom analyses on metabolic pathways and disease biomarkers. 3) Investigated genetic mutations in the Neanderthal genome. 4) Developed and optimized Nextflow pipelines for high-throughput NGS data analysis.

Researched small molecule inhibitors targeting mitochondrial DNA transcription, focusing on mitochondrial proteins in metabolic disorders. Developed therapeutic strategies for obesity-related insulin resistance and type 2 diabetes using obese mouse models. Led in silico experiments and multi-omics data analysis to uncover key insights into the pathophysiology of metabolic diseases.

My research focuses on the maintenance and expression of mitochondrial DNA (mtDNA) in disease and aging models. I investigate the regulation of mtDNA-encoded genes essential for mitochondrial transcription and replication. Using genetically modified mouse models, I study mitochondrial RNA (mtRNA) processing and its role in disease mechanisms and aging.

Investigated protein prenylation in the pathogenesis of obesity-related non-alcoholic fatty liver disease, insulin resistance, and type 2 diabetes, focusing on its potential as a therapeutic target. Validated small molecule inhibitors of protein prenylation in treating insulin resistance and fatty liver disease through in vitro and in vivo studies. Extensive experience with in vitro cell models and in vivo mouse models for studying metabolic disorders, contributing to novel therapeutic strategies.